Most health economists people know quality adjusted life years (QALYs) are. But why are they so widely used in the United Kingdom, but not in the ...
admin
Last week, the Congressional Budget Office (CBO) released a report titled “How Changes to Funding for the NIH and Changes in the FDA’s Review Times ...
Many people don’t understand why pharmaceuticals cost so much money. Don’t pharmaceutical companies make a lot of money? The answer is ‘yes’, but only ...
Catastrophic healthcare expenditures (CHE) are highly problematic for families are are unequally distributed throughout society. However, how can we ...
Conventional wisdom holds that orphan drugs treat rare (by definition) and more severe diseases. Because they treat ...
Myself and Kristy Piccinini, PhD from FTI Consulting published a new commentary in The Evidence Base titled ...
On this blog we most often talk about health care issues related to chronic and acute conditions, health behaviors and ...
That is the title of my new paper in the Forum for Health Economics and Policy (FHEP) and the subtitle is “Estimating Insurance Value and Risk ...
Yesterday, the UK government released it’s Life Sciences Sector Plan (LSSP). The British government summarized the provisions as follows: 1. ...
About this Episode This week’s interview wasn’t initially intended for the podcast and wasn’t recorded that way ...
